title: [Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].
abstract: Simplification of triple antiretroviral therapy to lopinavir/ritonavir (LPV/r) monotherapy in patients with well-controlled viremia for prolonged periods (more than 6 months) without prior failure with a protease inhibitor has been proposed as a strategy that could reduce the toxicity and costs of antiretroviral therapy in the long term while also preserving other therapeutic options. The results of several studies are currently available, some of which had a large number of patients and follow-up of up to 4 years. These studies indicate that this strategy is safe and efficacious, thus allowing its clinical use when indicated. This strategy may be especially useful in reducing the costs of treatment in countries with scarce economic resources. The role of LPV/r monotherapy in the prevention and management of lipodystrophy and in improving the selection of patients with an optimal risk-benefit ratio remains to be defined.
authors: Unidad VIH, Hospital Universitario 12 de Octubre, Madrid, España. federicopulido@med.ucm.es
authors: Federico
authors: F
authors: Pulido Ortega
authors: Jara
authors: J
authors: Llenas-García
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003363:Cost Control; D003906:Developing Countries; D004338:Drug Combinations; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000502:physiology; D039682:HIV-Associated Lipodystrophy Syndrome / Q000517:prevention & control; D006801:Humans; D061466:Lopinavir; D015337:Multicenter Studies as Topic; D010865:Pilot Projects; D011446:Prospective Studies; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy; D014779:Virus Replication / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir